165 related articles for article (PubMed ID: 31742696)
21. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Choi JK; Berkman CE
Prostate; 2009 May; 69(6):585-94. PubMed ID: 19142895
[TBL] [Abstract][Full Text] [Related]
22. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
[TBL] [Abstract][Full Text] [Related]
23. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
24. Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy.
Nakajima K; Miyazaki F; Terada K; Takakura H; Suzuki M; Ogawa M
Int J Pharm; 2021 Nov; 609():121135. PubMed ID: 34571072
[TBL] [Abstract][Full Text] [Related]
25. Photodynamic therapy for prostate cancer - A narrative review.
Osuchowski M; Bartusik-Aebisher D; Osuchowski F; Aebisher D
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102158. PubMed ID: 33352313
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
27. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
[TBL] [Abstract][Full Text] [Related]
28. A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation.
Capozza M; Stefania R; Dinatale V; Bitonto V; Conti L; Grange C; Skovronova R; Terreno E
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361667
[TBL] [Abstract][Full Text] [Related]
29. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
30. Antibody-drug conjugates targeting prostate-specific membrane antigen.
Olson WC; Israel RJ
Front Biosci (Landmark Ed); 2014 Jan; 19(1):12-33. PubMed ID: 24389170
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
32. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
33. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
36. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
37. Ce6-Modified Carbon Dots for Multimodal-Imaging-Guided and Single-NIR-Laser-Triggered Photothermal/Photodynamic Synergistic Cancer Therapy by Reduced Irradiation Power.
Sun S; Chen J; Jiang K; Tang Z; Wang Y; Li Z; Liu C; Wu A; Lin H
ACS Appl Mater Interfaces; 2019 Feb; 11(6):5791-5803. PubMed ID: 30648846
[TBL] [Abstract][Full Text] [Related]
38. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.
Liu T; Wu LY; Choi JK; Berkman CE
Int J Oncol; 2010 Apr; 36(4):777-84. PubMed ID: 20198319
[TBL] [Abstract][Full Text] [Related]
39. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
[TBL] [Abstract][Full Text] [Related]
40. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]